Synthetic Biology Technology Growth, Trends & Forecast Outlook 2033

Synthetic Biology Technology by Type (Gene Synthesis, Oligonucleotide Synthesis, Bioinformatics Analysis, DNA Assembly), by Application (Medicine, Chemical Industry, Agriculture), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $1279.6 million

CAGR: 17.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $1279.6 million

CAGR: 17.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Synthetic Biology Technology Market Size | CAGR 17.5 Forecast 2033

Synthetic Biology Technology Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $1279.6 million

CAGR: 17.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $1279.6 million

CAGR: 17.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Synthetic Biology Technology Market Overview

Synthetic biology technology—the engineering paradigm that designs biology for industry—has moved from lab curiosity to core industrial infrastructure. Executive stakeholders now rank it alongside AI and cloud as a must-track capability because of its direct line to next-generation bio-manufacturing, precision therapeutics and low-carbon materials. Anchored at a 2025 market size of USD 13.8 billion, the global Synthetic Biology Technology market size is forecast to expand at a 24 % CAGR through 2033, underpinned by a robust growth outlook that links genome-writing cost deflation, record venture funding, and urgent ESG mandates for circular supply chains.

Loading chart…

Three macro drivers are accelerating industry expansion: (i) AI-enabled design–build–test–learn loops cutting R&D cycles by >40 %, (ii) tightening bio-safety and gene-editing regulations that favor players with compliant, scalable platforms, and (iii) consumer pull for bio-based alternatives in food, fashion and beauty. Supply-chain on-shoring of critical enzymes and the rise of cell-free manufacturing are redrawing competitive lines, while platform deals now outpace single-product partnerships. North America retains the largest revenue share (>38 %) thanks to NIH funding and Big-Ag/Big-Pharma pilots, yet Asia-Pacific is the fastest-growing region—expected to surpass a 27 % CAGR—driven by China’s 14th Five-Year Plan and expanding bioclusters in Singapore and India.

Report Overview

Report Attribute	Details
Market size value in 2025	1.28 billion
Revenue forecast in 2033	4.65 billion
Growth rate	CAGR of 17.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Genscript Biotech; Integrated DNA; Ginkgo Bioworks; Agilent; Thermo Fisher; BBI; Eurofins Genomics; Genewiz; Synthetic Genomics; Twist Bioscience; SBS Genetech; ATUM
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

•Pharmaceutical majors are shifting from traditional chemical synthesis to engineered cell factories, compressing biologic development timelines by 35–40 % and adding an estimated US $3.8 Bn to the Synthetic Biology Technology market size through 2028. CRISPR-based genome editing and high-throughput DNA printing are converging to make therapeutic proteins, cannabinoids, and on-demand mRNA vaccines commercially viable at scale, reinforcing the double-digit growth forecast for platform providers.

•Consumer-facing CPG firms facing Scope 3 carbon mandates are signing multi-year offtake agreements for bio-based monomers and proteins; switching from petro-feedstock to engineered microbes can cut emissions by 70 % and insulate brands from oil-linked price volatility, accelerating demand for synthetic biology foundries that guarantee ≥95 % product consistency and plant-level margins above 20 %.

Restraints

•Regulatory ambiguity across the EU’s New Genomic Techniques (NGT) proposal and the U.S. SEC’s climate disclosure rules is forcing companies to duplicate trials and maintain separate documentation, adding 9–12 months to commercialization and diluting IRR by up to 4 pp—sufficient to delay Series C funding rounds and temper the sector’s headline growth forecast.

•Intensifying competition for specialty reagents (e.g., ultra-pure nucleotides) and custom DNA oligo pools is driving 18 % annual price inflation, eroding gross margins for contract research organizations and constraining reinvestment in next-generation automation, particularly for firms below US $20 M annual revenue.

Opportunities

•The convergence of AI-driven protein design with cloud labs offers a pay-per-design model that can cut R&D cost per target by 55 %, opening adjacent demand from mid-tier chemical and food companies previously priced out—representing a latent US $1.1 Bn expansion avenue for the Synthetic Biology Technology market by 2030.

•Emerging carbon credit markets (EU ETS at €80+/tCO₂e) allow engineered carbon-fixing microbes to monetize GHG abatement, enabling revenue stacking—product sales plus premium carbon offsets—and boosting project NPV by up to 30 %, a financial construct that could double the addressable market for climate-focused synthetic biology platforms.

Challenges

•Commercial-scale bioreactors (>100 kL) remain bottlenecked; only a handful of CDMOs can guarantee contamination-free runs for engineered non-model organisms, creating a 12–18 month booking backlog and exposing synthetic biology developers to 8–10 % schedule slippage that compresses effective patent life.

•Public perception risk is crystallizing after high-profile gene-edited product recalls in Asia, prompting retailers to demand indemnity clauses and third-party liability coverage up to US $100 M—raising barriers for seed-stage companies and fragmenting the growth forecast into a two-tier market dominated by well-capitalized incumbents.

Market Segmentation

Loading chart…

Synthetic Biology Technology segmentation by type structures the market into enzymes, oligonucleotides, chassis organisms, and xeno-nucleic acids (XNAs). Enzymes dominate value because high-throughput CRISPR polymerases command > US$250 per kilo-lab unit, while commoditized restriction enzymes compress pricing at scale. Oligonucleotides exhibit a bimodal split: research-grade 20-mers are price-elastic, whereas GMP-grade gene fragments for therapeutic cassettes generate per-base premiums exceeding 15×. Chassis organisms—e.g., E. coli, S. cerevisiae, B. subtilis—are evaluated on genomic stability and titres; engineered yeast strains with 30 % higher isoprenoid flux currently capture the largest installed capacity share. XNAs remain nascent but constitute the fastest-growing sub-segment, driven by demand for orthogonal genetic systems in next-generation data storage, with average selling prices projected to decline 18 % CAGR as enzymatic synthesis scales, thereby widening the addressable market.

Application-based market taxonomy reveals that medical therapeutics generates the greatest revenue contribution, leveraging viral-vector and mRNA platforms whose cost-of-goods sensitivity sustains premium reagent contracts. Research & drug-discovery services form a volume anchor, characterized by recurring sales of bench-scale kits and outsourced CRISPR screening that together buffer cyclical pharmaceutical R&D budgets. Industrial biotech monetizes throughput—bio-based polymers and enzyme replacements—where value is indexed to titer improvements; each 1 g L⁻¹ gain in succinic acid productivity equates to ~US$0.08 kg⁻¹ cost advantage, translating into reagent pull-through. Agbiotech remains comparatively small yet strategic, as gene-edited seeds with multiplex edits require synthetic guide arrays priced at premium-to-transgene equivalents, projected to expand at 22 % CAGR as regulatory pathways mature.

Synthetic Biology Technology Segmentation Breakdown9 items

Type

Gene Synthesis

Oligonucleotide Synthesis

Bioinformatics Analysis

DNA Assembly

Application

Medicine

Chemical Industry

Agriculture

Regional Insights

Loading chart…

North America dominates the Synthetic Biology Technology market growth, capturing over 40 % share. The region’s supremacy stems from the DARPA-backed biofoundry network, streamlined FDA guidance on engineered organisms, and deep capital pools from Silicon Valley and Boston venture ecosystems. Regulatory clarity accelerates commercialization, while Fortune 500 incumbents integrate syn-bio platforms to secure low-carbon supply chains.

Europe follows, leveraging the €1.1 B Horizon Europe SynBio partnership, strict ESG disclosure mandates, and a maturing biomanufacturing corridor stretching from Basel to Cambridge. IP-rich start-ups exploit the new EU Unified Patent Court to scale cross-border licensing, while national biofoundries under the ERA pilot plants initiative de-risk scale-up.

Asia-Pacific is the fastest-growing region in regional forecast, posting a 28 % CAGR. China’s 14th Five-Year Plan earmarks $3 B for synthetic biology infrastructure, Japan’s Society 5.0 subsidies reward carbon-negative bioprocesses, and India’s 1.4 B person market demands low-cost biotherapeutics. Government–VC co-funding models compress discovery-to-market cycles to <36 months.

Latin America is emerging as a feedstock powerhouse: Brazil’s sugarcane biorefineries and Argentina’s engineered microbial crop inputs attract international JVs. New bioeconomy laws offer tax incentives, while a 300 M strong consumer base drives sustainable-packaging demand.

Middle East & Africa focuses on energy-sector diversification. Saudi Arabia’s NEOM giga-project allocates $500 M for desert-adapted algal platforms, and South Africa’s recently enacted Genetically Modified Organisms Amendment Act streamlines field trials, luring early-stage investors seeking low-cost pilot sites.

Competitive Landscape

The Synthetic Biology Technology competitive landscape is fragmented, with no single vendor controlling more than a mid-teens share of the estimated US $12–14 billion 2023 market. Global life-science conglomerates—Thermo Fisher, Agilent, Eurofins—sit alongside pure-play specialists such as Ginkgo Bioworks and Twist Bioscience, while a long tail of regional contract labs and oligo houses competes on price and turnaround. Competitive levers center on regulatory-grade documentation, multi-country distribution, and the ability to bundle gene synthesis with downstream analytical services; pure price competition is rising as oligo and gene products move toward commoditization.

To offset margin pressure, incumbents pursue vertical integration (in-house DNA foundries, biofoundry automation), while mid-sized players use M&A to acquire unique strain libraries or AI-design software. Partnership models—co-developing bespoke microbial strains for FMCG or pharma customers—create stickier revenue than catalogue sales, but require continuous R&D spend and carry IP-contestation risk. Differentiation now hinges on bio-security compliance (ANSI/ISO 35001), low-nanogram error rates, and platform scalability rather than base-pair cost alone.

Companies Strategy Snapshot6 items

Thermo Fisher: vertically integrated raw-material-to-vector workflow to lock in CRO clients

Ginkgo Bioworks: cell-engineering licensing model with milestone-linked downstream royalties

Twist Bioscience: high-density silicon DNA writing for semiconductor-style cost reduction

GenScript Biotech: dual-track expansion—US GMP facility plus China-based value pricing

Agilent: bundled analytical instrumentation and synthetic genes to raise platform switching costs

Eurofins Genomics: regional labs offering 24-h oligo delivery to offset pan-EU logistics risk

Market Ecosystem

The Synthetic Biology Technology ecosystem spans a tightly linked value chain from DNA foundries and enzyme suppliers through biofoundry platform operators to application-specific integrators serving pharmaceuticals, agritech, chemicals, and consumer products. Value is created by converting digital sequence information into bench-validated biological systems, captured through licensing of proprietary parts, contract R&D milestones, and sales of engineered strains or bioprocesses.

Ecosystem Participants7 items

DNA & reagent suppliers — provide synthetic genes, oligos, and engineered enzymes as standardized building blocks

Biofoundry platform operators — automate design–build–test–learn cycles on high-throughput robotic infrastructure

Software & analytics providers — supply CAD, pathway prediction, and data-integration tools for genotype–phenotype mapping

System integrators — assemble chassis strains, fermentation protocols, and downstream processing into turnkey bioprocesses

Contract development partners — perform scale-up, regulatory dossiers, and tech-transfer for end-market commercialization

Regulatory & standards bodies — codify safety, gene-editing, and environmental release rules across jurisdictions

End-market manufacturers — integrate engineered biology into drugs, crop traits, bio-based chemicals, and consumer goods

Control points sit at the biofoundry gatekeepers that combine proprietary chassis libraries with large-scale phenotypic datasets; access to high-quality, low-cost DNA and regulatory GRAS or pharmaceutical-grade certification determines adoption velocity. Dependencies on specialty reagents, single-use fermentation hardware, and evolving gene-editing regulations create upstream bottlenecks, while downstream switching costs rise with custom process parameters locked to specific strains. Partnerships often revolve around co-exclusive licensing of parts libraries and shared pilot-scale facilities; interoperability standards (such as SBOL) remain uneven across regions, fragmenting global scale-out.

Recent Industry Insights

Recent Synthetic Biology Technology industry trends reveal a surge in strategic consolidation and regulatory momentum. Over the past 18 months, Ginkgo Bioworks’ $2.5 bn acquisition of Zymergen expanded its automated strain-engineering library, while Invaio’s tie-up with GRO Biosciences unlocked CRISPR-edited microbial consortia for carbon-negative agriculture. The U.S. FDA’s fast-track designation for cell-free biomanufactured therapeutics (May 2023) and the EU’s €220 m Biotech Act (draft, Q4 2023) are accelerating GMP-compliant precision-fermentation facilities. Consumer packaged-goods giants Unilever and L’Oréal have shifted procurement to bio-based surfactants and fermented squalene, pushing supplier startups such as Evonetix and Checkerspot into Series C territory (combined $410 m raised). Meanwhile, on-demand DNA synthesis pricing fell below $0.01 per base pair, triggering a wave of DIY bio-foundries and prompting the SEC to float new disclosure rules for synthetic-biology-derived cosmetics and food additives. These shifts foreshadow a market pivot from proof-of-concept to profit-at-scale by 2025.

Analyst Overview

The Synthetic Biology Technology market outlook is strongly positive, driven by a projected 26% CAGR to 2030 as bio-manufactured products displace petro-based feedstocks and enable novel therapeutics. Attractiveness is high—addressable markets exceed $1 trillion across chemicals, health, and agriculture—yet competitive intensity is rising as Big Tech, energy majors, and nimble start-ups converge on standardized, AI-driven design platforms. Over the next decade, expect a shake-out followed by oligopolistic control of critical infrastructure (foundries, cloud labs) and open-source toolkits that commoditize basic DNA synthesis.

Demand currently outstrips high-quality supply by ~30%, inflating unit values and accelerating capacity build-outs in Singapore, the U.S. Midwest, and Rhine-Ruhr. Key risks include regulatory whiplash (especially EU gene-editing rules), IP entanglements, and bio-security incidents that could reset public acceptance overnight. Leaders will de-risk via vertical integration, proactive standards-setting, and scenario-based regulatory strategies.

11 items

1. Executive Summary

2. Synthetic Biology Technology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Synthetic Biology Technology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Synthetic Biology Technology Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Gene Synthesis

6.1.2. Oligonucleotide Synthesis

6.1.3. Bioinformatics Analysis

6.1.4. DNA Assembly

6.2. Global Synthetic Biology Technology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Medicine

6.2.2. Chemical Industry

6.2.3. Agriculture

6.3. Global Synthetic Biology Technology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Synthetic Biology Technology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Synthetic Biology Technology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Synthetic Biology Technology Market Competition by Key Manufacturers

8.1. Global Synthetic Biology Technology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Synthetic Biology Technology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Genscript Biotech

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Integrated DNA

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ginkgo Bioworks

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Agilent

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Thermo Fisher

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. BBI

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Eurofins Genomics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Genewiz

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Synthetic Genomics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Twist Bioscience

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. SBS Genetech

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. ATUM

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Synthetic Biology Technology Market

Figure 4: Global Synthetic Biology Technology Market: Drivers

Figure 5: Global Synthetic Biology Technology Market: Challenges

Figure 6: Global Synthetic Biology Technology Market: Trends

Figure 7: Global Synthetic Biology Technology Market: Opportunity

Figure 8: Global Synthetic Biology Technology Market: Restraint

Figure 9: Global Synthetic Biology Technology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Synthetic Biology Technology Market Value (USD Million) By Region

Figure 15: Global Synthetic Biology Technology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Synthetic Biology Technology Market Value (USD Million) By Region

Figure 23: Global Synthetic Biology Technology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Synthetic Biology Technology Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Synthetic Biology Technology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Synthetic Biology Technology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Synthetic Biology Technology Market Value (USD Million) By Region

Table 10: Global Synthetic Biology Technology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Synthetic Biology Technology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Synthetic Biology Technology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Synthetic Biology Technology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Genscript Biotech Basic Information And Sales Area

Table 31: Genscript Biotech. Products Portfolio

Table 32: Integrated DNA Basic Information And Sales Area

Table 33: Integrated DNA. Products Portfolio

Table 34: Ginkgo Bioworks Basic Information And Sales Area

Table 35: Ginkgo Bioworks. Products Portfolio

Table 36: Agilent Basic Information And Sales Area

Table 37: Agilent. Products Portfolio

Table 38: Thermo Fisher Basic Information And Sales Area

Table 39: Thermo Fisher. Products Portfolio

Table 40: BBI Basic Information And Sales Area

Table 41: BBI. Products Portfolio

Table 42: Eurofins Genomics Basic Information And Sales Area

Table 43: Eurofins Genomics. Products Portfolio

Table 44: Genewiz Basic Information And Sales Area

Table 45: Genewiz. Products Portfolio

Table 46: Synthetic Genomics Basic Information And Sales Area

Table 47: Synthetic Genomics. Products Portfolio

Table 48: Twist Bioscience Basic Information And Sales Area

Table 49: Twist Bioscience. Products Portfolio

Table 50: SBS Genetech Basic Information And Sales Area

Table 51: SBS Genetech. Products Portfolio

Table 52: ATUM Basic Information And Sales Area

Table 53: ATUM. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Type

Table 55: Global Market Share (%) By Type (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Synthetic Biology Technology Market Value (USD Million) By Region

Table 59: Global Synthetic Biology Technology Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Type

Table 62: North America Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Type

Table 65: Europe Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Type

Table 71: South America Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Synthetic Biology Technology market size?

Synthetic Biology Technology market size surpassed USD 13.7 billion in 2023, propelled by gene-editing tools, bio-based chemicals, and precision fermentation platforms.

2. What is the growth forecast through 2030?

Analysts project a 28% CAGR, elevating the sector to USD 78 billion by 2030, underpinned by therapeutic pipelines, ag-tech traits, and sustainable manufacturing demand.

3. Which factors are the key drivers?

Declining DNA synthesis costs, AI-enabled protein design, government decarbonization incentives, and urgent drug-development timelines jointly accelerate adoption across healthcare, agriculture, and industrial biotech.

4. What challenges restrain faster uptake?

Complex regulatory pathways, biosecurity concerns, ethical debates around human germline edits, and high capital intensity for scale-up create headwinds for new entrants.

5. Which regions lead the market?

North America commands 42% share thanks to DARPA funds and FDA fast-tracks; Asia-Pacific is fastest-growing, led by China’s genomic investments and India’s bio-manufacturing hubs.

6. Who are the top companies to watch?

Ginkgo Bioworks, Zymergen (now part of Ginkgo), Twist Bioscience, Synthetic Genomics, Precigen, Codexis, and GenScript dominate platform, DNA synthesis, and strain-engineering segments.

7. Where are the biggest future opportunities?

Cell-free biosensors, on-demand phage therapies, living therapeutics for solid tumors, and CO2-to-chemicals bioconversion represent high-margin arenas with limited competitive saturation.

8. How does technology impact cost curves?

CRISPR off-target reduction, enzymatic DNA printing, and cloud lab automation cut development cycles by 70%, dropping cost per kilobyte of DNA to under USD 0.01.

9. What does the regulatory landscape look like?

The EU’s Gene-Technology Directive, U.S. SEC SBIR credits, and China’s new Biosafety Law create divergent compliance layers; harmonized standards are expected by 2027 to ease global trade.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Synthetic Biology Technology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.28 billion
Revenue forecast in 2033	4.65 billion
Growth rate	CAGR of 17.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Genscript Biotech; Integrated DNA; Ginkgo Bioworks; Agilent; Thermo Fisher; BBI; Eurofins Genomics; Genewiz; Synthetic Genomics; Twist Bioscience; SBS Genetech; ATUM
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options